ACR Meeting Abstracts

ACR Meeting Abstracts

  • Meetings
    • ACR Convergence 2024
    • ACR Convergence 2023
    • 2023 ACR/ARP PRSYM
    • ACR Convergence 2022
    • ACR Convergence 2021
    • ACR Convergence 2020
    • 2020 ACR/ARP PRSYM
    • 2019 ACR/ARP Annual Meeting
    • 2018-2009 Meetings
    • Download Abstracts
  • Keyword Index
  • Advanced Search
  • Your Favorites
    • Favorites
    • Login
    • View and print all favorites
    • Clear all your favorites
  • ACR Meetings

Abstract Number: 2863

Copy Number Variations Of Complement C4A and C4B Genes Are Genetic Risk Factor and Disease Modification Factor, Respectively, For Juvenile Dermatomyositis

Anjali Patwardhan1, Katherine Lintner2, Lisa G. Rider3, Frederick W. Miller3, Terrance O'Hanlon3, Yee Ling Wu4, Bi Zhou2, Huanyu Wang4, David Newsom5, Peter White5, Charles H. Spencer6 and C. Yung Yu2, 1Pediatric Rheumatology, University of Missouri Women's and Children's Hospital, Columbia, MO, 2Center for Molecular and Human Genetics, The Research Institute at Nationwide Children's Hospital and The Ohio State University, Columbus, OH, 3Environmental Autoimmunity Group, NIEHS, NIH, Bethesda, MD, 4The Research Institute at Nationwide Children's Hospital and The Ohio State University, Columbus, OH, 5Biomedical Genomics Core, The Research Institute at Nationwide Children's Hospital and The Ohio State University, Columbus, OH, 6Rheumatology, Nationwide Childrens Hospital, Columbus, OH

Meeting: 2013 ACR/ARHP Annual Meeting

Keywords: Complement deficiency and juvenile dermatomyositis

  • Tweet
  • Click to email a link to a friend (Opens in new window) Email
  • Click to print (Opens in new window) Print
Session Information

Title: Pediatric Rheumatology - Pathogenesis and Genetics

Session Type: Abstract Submissions (ACR)

Background/Purpose:

Juvenile Dermatomyositis (JDM) is a systemic and inflammatory vasculopathy that affects mainly proximal muscles and skin in children.  It is a rare but severe autoimmune disease featuring the presence of autoantibodies against the translational machinery for protein synthesis. Proteolytic products of antibody-mediated complement activation are often observed in affected tissues of JDM.  The causal factors for JDM are unknown, but genetic variants of the HLA are strongly implicated, particularly in haplotypes with HLA-DR3.  Recently, differential copy number variations (CNVs) for the HLA-associated complement C4A and C4B genes were demonstrated in healthy subjects and autoimmune disease patients. A deficiency of C4A is strongly associated with HLA-DR3 and systemic autoimmunity.  Our objective is to investigate CNVs of total C4, C4A, and C4B on the pathogenesis of JDM.

Methods:

The study population included 56 JDM patients (53 Whites, 3 Blacks) and 577 geographically matched healthy subjects, recruited upon informed consents according to IRB-approved protocols. The mean (±SD) age for JDM disease diagnosis was 7.91±4.27 years old.  Calcinosis, lipodystrophy, and skin ulceration were observed in 19.6%, 9.1% and 16.1% of patients, respectively.  Genomic DNA, PAXGENE RNA, and EDTA-plasma were isolated from peripheral blood samples. Gene copy numbers (GCN) for total C4, C4A, and C4B were determined by genomic Southern blot and TaqMan-based, realtime qPCR.  Global gene expression array were determined using PAXGENE RNA and Agilent SurePrint G3 8x60K microarrays.  The expression of IFI44 was determined by SYBR-Green based qPCR using PAXGENE RNA and GADPH as standard.

Results:

Among White subjects, the GCNs vary from 2 to 6 for total C4, 0 to 5 for C4A, and 0 to 4 for C4B.  There were significant decreases in JDM (vs. controls) for GCNs of total C4 (cases: 3.42±0.72, controls: 3.85±0.69; p=0.00007, t-test) and C4A (cases: 1.74±0.86, controls: 2.10±0.76; p=0.0009, t-test).  Remarkably, 43.4% of the JDM patients had a heterozygous or homozygous deficiency of C4A, compared to 18.5% in controls (p=0.00008, Χ2analysis). The odds ratio (95% CI) for C4A deficiency in JDM was 3.37 (1.88- 6.04).  Intra-group comparison of clinical presentations revealed that patients with calcinosis and lipodystrophy both had significantly higher GCN of C4B (p=0.001, Fisher’s exact), reflecting a role of C4B in complement-mediated tissue injuries. Global gene expression studies using peripheral blood RNA (19 JDM, 8 controls) and Agilent microarrays revealed up-regulation of genes typical for interferon-α response signature and down-regulation for chemokine genes. SYBR-green labeled qPCR on transcripts for IFN-α response gene IFI44 showed a 4.7 and 2.6 -fold increase in expression among patients with and without a C4A deficiency, respectively, vs. controls (p=0.004, t-test).

Conclusion:

A deficiency of C4A is a common genetic risk factor for JDM with medium to high effect size. Peripheral blood RNA from JDM exhibited upregulation of IFN-α response gene IFI44, particularly among C4A deficient patients. Among established JDM patients, normal/high GCN of C4B was associated with disease complications, including calcinosis and lipodystrophy.


Disclosure:

A. Patwardhan,
None;

K. Lintner,
None;

L. G. Rider,
None;

F. W. Miller,
None;

T. O’Hanlon,
None;

Y. L. Wu,
None;

B. Zhou,
None;

H. Wang,
None;

D. Newsom,
None;

P. White,
None;

C. H. Spencer,
None;

C. Y. Yu,
None.

  • Tweet
  • Click to email a link to a friend (Opens in new window) Email
  • Click to print (Opens in new window) Print

« Back to 2013 ACR/ARHP Annual Meeting

ACR Meeting Abstracts - https://acrabstracts.org/abstract/copy-number-variations-of-complement-c4a-and-c4b-genes-are-genetic-risk-factor-and-disease-modification-factor-respectively-for-juvenile-dermatomyositis/

Advanced Search

Your Favorites

You can save and print a list of your favorite abstracts during your browser session by clicking the “Favorite” button at the bottom of any abstract. View your favorites »

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].

Wiley

  • Online Journal
  • Privacy Policy
  • Permissions Policies
  • Cookie Preferences

© Copyright 2025 American College of Rheumatology